Leinco Technologies

Anti-Human TACE (CT)

Product Code:
 
LEI-T203
Product Group:
 
Primary Antibodies
Host Type:
 
Rabbit
Antibody Clonality:
 
Polyclonal
Regulatory Status:
 
RUO
Target Species:
 
Human
Applications:
  • Immunohistochemistry- Paraffin Embedded (IHC-P)
  • Western Blot (WB)
Shipping:
 
Ambient
Storage:
 
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-T203-20ug20 ug£199.00
Quantity:
LEI-T203-0.1mg0.1 mg£591.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
PN:T204
Long Description:
TACE (tumor necrosis factor-α-converting enzyme) is a pleiotropic metalloprotease also known as ADAM17 that is found to be constitutively expressed by intestinal epithelial cells.1 TACE is a major sheddase of TNF-α and its receptors, essential for the generation of soluble, mature molecules.2 TACE as a promising target of epidermal growth factor receptor (EGFR) axis inhibition in colorectal cancer (CRC)3 and a principal target for the treatment of TNF-dependent pathologies.4
Target:
TACE

References

1. Masson, D. et al. (2009) Int J Mol Med. 23: 41 2. Chodynicka, B. et al. (2008) J European Acad Dermatol & Venereol. 22: 712 3. Coffey, RJ. et al. (2008) Clin Cancer Res. 14: 1182 4. Blobel, CP. et al. (2007) J Immunol. 179: 2689